By Fineline Cube 
US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion in revenues for the first quarter, representing a 9% year-on-year (YOY) increase. Product sales grew by 11% to USD 5.662 billion, driven by a 14% increase in volume, partially offset by a 6% decrease in net selling price.
Key Product Performance
Fourteen products delivered at least double-digit sales growth in the first quarter. Notable performers included Repatha (evolocumab) with a 27% increase, Evenity (romosozumab-aqqg) with a 29% increase, Blincyto (blinatumomab) with a 52% increase, Tezspire (tezepelumab-ekko) with a 65% increase, Tavneos (avacopan) with a 76% increase, and Uplizna (inebilizumab-cdon) with a 14% increase.
Core Product Sales Data
| Trade name | Generic name | Total sales (USD mil.) | YOY Growth rate |
|---|---|---|---|
| Repatha | Evolocumab | 6.56 | 27% |
| Evenity | Romosozumab | 4.42 | 29% |
| Prolia | Denosumab | 10.99 | 10% |
| Uplizna | Inebilizumab | 0.91 | 14% |
| Tavneos | Avacopan | 0.90 | 76% |
| Tezspire | Tezepelumab | 2.85 | 65% |
| Otezla | Apremilast | 4.37 | 11% |
| Blincyto | Blinatumomab | 3.70 | 52% |
Full-Year Revenue Outlook
The company expects full-year revenues for 2025 to fall between USD 34.3 billion and USD 35.7 billion.-Fineline Info & Tech